STOCK TITAN

Oracle and Buck Institute for Research on Aging Advance Landmark Federal Aging Research Initiative

Oracle will provide AI-enabled analytics and large-scale health data to support Buck Institute and federal THRIVE aging research under ARPA-H’s PROSPR program.

(Neutral)
(Neutral)
Tags

Oracle (ORCL) and the Buck Institute for Research on Aging are collaborating to use Oracle Life Sciences Data Intelligence to advance research on age-related diseases.

The Buck Institute will analyze more than 122 million de-identified longitudinal Oracle Health Real-World Data records to identify biomarkers that could enable early detection and targeted interventions for aging-related complications. The work supports the Stanford-led THRIVE consortium within ARPA-H’s PROSPR program and aims to help develop a validated FDA-grade “Intrinsic Capacity Score” to measure physical and mental capacity, predict long-term health trajectories, and accelerate aging-related clinical trials.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Key Figures

De-identified longitudinal records: 122 million+ records
De-identified longitudinal records
122 million+ records
Oracle Health Real-World Data; patients may appear more than once across health systems

Historical Context

1 past event · Latest: Sep 22
1 event
  1. Sep 22

    Platform recognition

    24h Move
    +0.4%

    Named leader in life-sciences R&D data platforms; assessment cited 122 million records.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bioinformatics, biomarkers, real-world data, pharmacovigilance
4 terms
bioinformatics technical
"aims to advance bioinformatics using Oracle Life Sciences Data Intelligence"
The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.
biomarkers medical
"research biomarkers that aim to enable early detection"
Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.
real-world data medical
"de-identified longitudinal Oracle Health Real-World Data records"
Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.
pharmacovigilance medical
"clinical trials, pharmacovigilance, and commercialization"
Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Buck Institute aims to advance bioinformatics using Oracle Life Sciences Data Intelligence to transform aging research into a predictive, data-driven science

ORLANDO, Fla., Sept. 23, 2026 /PRNewswire/ -- Oracle Health and Life Sciences Summit -- Oracle and the Buck Institute for Research on Aging are collaborating to advance intelligence into age-related disease and support discoveries that can extend the healthy years of life. Buck will leverage Oracle Life Sciences Data Intelligence, which encompasses 122 million+* de-identified longitudinal Oracle Health Real-World Data records and advanced analytics to research biomarkers that aim to enable early detection and targeted intervention for aging-related complications. The research will also be used to pursue qualification for the first FDA-grade "Intrinsic Capacity Score," a vitality score for healthy aging.

Decoding Age-Related Illnesses
The Buck Institute serves as one of the analytics and bioinformatics engines for the Stanford University-led Transforming Health: Reclaiming Intrinsic Vitality for Everyone (THRIVE) consortium of scientists. THRIVE is a component of the PROactive Solutions for Prolonging Resilience (PROSPR) program from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services. The THRIVE team's goal is to develop a validated measure of physical and mental capacity designed to help predict long-term health trajectories and enable earlier interventions for age-related decline in a patient's health journey.

Using Oracle Life Sciences Data Intelligence, researchers at Buck Institute aim to construct patient cohorts and apply advanced analytics to decades of longitudinal health records to identify subtle clinical changes that may indicate frailty or chronic disease years before onset. The team plans to build a statistically validated model capable of predicting which patients are at greatest risk—and when—to support proactive care and accelerate the path to clinical trials for aging-related interventions.

"Understanding how and why we age is one of the most complex challenges in modern medicine," said Dr. David Furman, PhD, Buck Institute for Research on Aging. "Having the right solution and accessible patient data to aid in the study, discovery, and measurement of health span is essential. Oracle Life Sciences Data Intelligence, together with the depth and breadth of its real-world data, will enable us to begin to link early clinical signals and long-term outcomes. We hope to fundamentally change how to predict, delay, and address age-related decline."

With Oracle Life Sciences Data Intelligence, Buck Institute's researchers gain secure, hosted access to a vast repository of de-identified real-world health data. They can log in, build cohorts, run queries, and conduct bioinformatics workflows without extensive data preparation. This will help move more quickly from scientific hypothesis to analytical output in support of THRIVE's goals.

"Buck Institute is helping lead one of the most ambitious efforts to transform research on aging into a predictive science, and Oracle is proud to provide the data and analytics foundation to accelerate this work," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "By combining advanced AI-driven analytics with one of the industry's largest collections of de-identified longitudinal real-world health data, our solution can help researchers uncover earlier signals of age-related decline. This collaboration could reshape how we understand aging, and how to aid early intervention research to help people live healthier, longer lives."

Oracle Life Sciences Data Intelligence is a generative AI-enabled, cloud-native analytics environment that unifies owned, third-party, and real-world data into a single research-ready workspace. Built for life sciences organizations that need to move from data to insight without complex data engineering, the solution deploys AI capabilities that can clarify research intent, generate and refine hypotheses, propose analyses for review, and surface evidence within user-defined guardrails, with full visibility into data lineage.

To learn more about how Oracle Life Sciences Data Intelligence can accelerate discovery, clinical trials, pharmacovigilance, and commercialization, visit: https://www.oracle.com/life-sciences/data-intelligence/.

*All data pulled from Oracle Health Data Intelligence and current as of May 2026 and calculated using distinct person IDs, which leverage a multipoint match algorithm to account for and remove duplicates within a single health system; patients who have visited multiple health systems may appear more than once in the data.

This research was, in part, funded by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the United States Government.

About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements—empowering the life sciences industry to improve patient outcomes. Learn more at www.oracle.com/lifesciences.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

About the Buck Institute
Our success will ultimately change healthcare. At the Buck, we aim to end the threat of age-related diseases for this and future generations by bringing together the most capable and passionate scientists from a broad range of disciplines to identify and impede the ways in which we age. An independent, nonprofit institution, our goal is to increase human healthspan, or the healthy years of life. Globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor for serious diseases including Alzheimer's, Parkinson's, cancer, macular degeneration, heart disease, and diabetes, the Buck wants to help people live better longer. Learn more at: https://buckinstitute.org.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-buck-institute-for-research-on-aging-advance-landmark-federal-aging-research-initiative-302885590.html

SOURCE Oracle

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the THRIVE consortium and how does Buck Institute participate?

THRIVE (Transforming Health: Reclaiming Intrinsic Vitality for Everyone) is a Stanford University-led consortium that is part of ARPA-H’s PROSPR program. The Buck Institute serves as one of THRIVE’s analytics and bioinformatics engines and will use Oracle Life Sciences Data Intelligence to construct patient cohorts, run analyses on decades of health records, and support the development of validated measures of physical and mental capacity.

What is the intended purpose of the Intrinsic Capacity Score mentioned in the collaboration?

The project aims to help pursue qualification for the first FDA-grade “Intrinsic Capacity Score”, described as a vitality score for healthy aging. The score is intended to measure physical and mental capacity, support prediction of long-term health trajectories, and enable earlier interventions for age-related decline.

How will Oracle’s Life Sciences Data Intelligence platform be used by Buck Institute researchers?

Buck Institute researchers will have secure, hosted access to a large repository of de-identified real-world health data via Oracle Life Sciences Data Intelligence. They can log in to build cohorts, run queries, and conduct bioinformatics workflows without extensive data preparation, using advanced AI-driven analytics to move more quickly from scientific hypotheses to analytical outputs in support of THRIVE’s goals.

What is the scale and nature of the data Oracle is providing for this initiative?

The research leverages more than 122 million de-identified longitudinal Oracle Health Real-World Data records within Oracle Life Sciences Data Intelligence. The data are drawn from Oracle Health Data Intelligence as of May 2026 and are calculated using distinct person IDs that apply a multipoint match algorithm to remove duplicates within a single health system, while patients across multiple systems may appear more than once.

Who helped fund this research collaboration and what disclaimer is provided?

The research was funded in part by the Advanced Research Projects Agency for Health (ARPA-H). The announcement states that the views and conclusions in the document are those of the authors and should not be interpreted as representing the official policies, expressed or implied, of the United States Government.

Keep reading